Marinko Matosevic: Former Tennis Pro & Coach Banned 4 Years for Doping & Aiding Others

MELBOURNE, Australia – Former Australian tennis player and coach Marinko Matosevic has been handed a four-year suspension from all tennis activity, effective immediately, after being found guilty of multiple anti-doping rule violations between 2018 and 2020. The International Tennis Integrity Agency (ITIA) announced the sanction on Monday, bringing an complete to a case that has shaken the Australian tennis community.

The independent tribunal determined that Matosevic, 40, committed five separate breaches of the Tennis Anti-Doping Programme (TADP). These included the leverage of a prohibited method – specifically, blood doping even as an active player – and facilitating blood doping for another player. He was also found to have provided advice to other players on how to circumvent anti-doping tests, and to have used and possessed the prohibited substance clenbuterol, an anabolic agent.

Matosevic initially denied all charges, but admitted to blood doping in a statement to Australian media shortly before a scheduled hearing on February 9, 2026. The ITIA investigations, which began in 2024, uncovered compelling evidence of potential rule violations, leading to formal charges being laid in May 2025. Matosevic ultimately chose not to attend the hearing, despite multiple notifications.

“Matosevic’s actions went far beyond passive association and constitute intentional participation” in violation of the TADP, stated Michael Heron KC, chair of the independent tribunal, according to the ITIA’s release. The tribunal also dismissed allegations made by Matosevic questioning the integrity of the ITIA’s investigation, finding that the agency “acted within the authority conferred by the TADP.”

The case centers around a blood transfusion Matosevic received in Morelos, Mexico, in February 2018. He played qualifying at Indian Wells shortly after, marking the final tournament of his professional career, and officially announced his retirement later that year. At his peak, Matosevic reached a career-high ranking of world No. 39.

The suspension effectively bars Matosevic from any involvement in the sport, including coaching. He had recently been working with Australian players Chris O’Connell and Jordan Thompson, though neither is implicated in the investigation. He is prohibited from accessing any tournament or event sanctioned by the ITIA, encompassing both ATP and WTA tours.

The ITIA’s decision underscores the agency’s commitment to maintaining the integrity of professional tennis. The use of blood doping, which artificially enhances oxygen delivery to muscles, is a serious violation of anti-doping rules. Facilitating doping for others and providing advice on evading detection are also considered grave offenses.

Matosevic’s admission of blood doping came after a period of denial and criticism of the ITIA. In a statement published by The First Serve on February 2, 2026, he alleged a “corrupt process” and claimed he admitted to the doping charge due to the nature of the other accusations. Though, the tribunal rejected these claims.

The four-year ban will maintain Matosevic sidelined from the sport until 2030. The ITIA’s investigation and subsequent ruling serve as a stark reminder of the consequences of violating anti-doping regulations in professional tennis. The agency continues to emphasize its dedication to protecting the fairness and integrity of the game for all players and fans.

The fallout from this case is likely to be felt throughout the Australian tennis community, raising questions about the prevalence of doping and the effectiveness of anti-doping measures. The ITIA has not indicated whether further investigations are planned in connection with this case.

What’s Next: The ITIA will continue to monitor and enforce the TADP across all levels of professional tennis. The agency’s next major focus will be on ensuring compliance with anti-doping regulations during the upcoming Grand Slam season.

Archysport will continue to provide updates on this developing story.